Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/3072% below fair value
$5.79−0.10 (-1.70%)
Close on Nov 13, 2026Market cap $296.87MP/E –Yield –
Emergent BioSolutions price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Emergent BioSolutions's price to book ratio was 0.9× on Nov 11, 2026, against 1.0× a year earlier. Over the last 5 years it ranged from 0.1× to 1.7×, with a median of 0.8×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.9× | −0.2 |
| 2025 | Dec 31, 2025 | 1.1× | +0.1 |
| 2024 | Dec 31, 2024 | 1.0× | +0.8 |
| 2023 | Dec 29, 2023 | 0.2× | −0.2 |
| 2022 | Dec 30, 2022 | 0.4× | −1.1 |
| 2021 | Dec 31, 2021 | 1.5× | −2.3 |
| 2020 | Dec 31, 2020 | 3.8× | +1.1 |
| 2019 | Dec 31, 2019 | 2.7× | −0.4 |
| 2018 | Dec 31, 2018 | 3.1× | +1.0 |
| 2017 | Apr 28, 2017 | 2.0× | +0.0 |
| 2015 | Apr 30, 2015 | 2.0× | +0.0 |
| 2014 | Dec 31, 2014 | 2.0× | +0.2 |
| 2013 | Dec 31, 2013 | 1.8× | +0.4 |
| 2012 | Dec 31, 2012 | 1.4× | −0.2 |
| 2011 | Dec 30, 2011 | 1.6× | – |
See a number that looks wrong?